26 results about "Streptococcus pneumoniae" patented technology

Compositions comprising 5. salivarius strain SALI-10 and / or salivarius 10 peptide are taught. Also taught are methods of treating bacterial infections comprising administering a pharmaceutically acceptable amount of the composition to the patient with a bacterial infection caused by a pathogen from, for example, multi-drug resistant (MDR) Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus dysagalactiae, vancomycin-resistant Enterococcus faecium, Porphyromonas gingivalis, Tannerella forsythia, and MDR Enterococcus faecalis.

The invention belongs to the technical field of bacterium detection, and discloses a multiple PCR primer for simultaneously detecting eight respiratory tract pathogenic bacteria and application thereof. On the basis of a Luminex liquid phase chip technology, specific primers are designed aiming at eight common respiratory tract infection pathogenic bacteria including pseudomonas aeruginosa, staphylococcus aureus, streptococcus pneumoniae, klebsiella pneumoniae, acinetobacter baumannii, stenotrophomonas maltophilia, haemophilus influenzae and escherichia coli; the multiple PCR primers which are high in amplification efficiency, good in specificity and suitable for simultaneously detecting the eight respiratory tract pathogenic bacteria are screened out, the multiple PCR system and microsphere hybridization conditions are continuously optimized, the multiple PCR method for the eight respiratory tract pathogenic bacteria is successfully constructed by applying the Luminex xTAG technology, and the multiple PCR method can be applied to rapid detection of multiple pathogenic microorganisms.

The application discloses a bacillus licheniformis YL-001 with anti-inflammatory and antibacterial effects and an application thereof, and belongs to the technical field of biotechnology. The bacillus licheniformis YL-001 is separated from soil. The preservation number of the bacillus licheniformis is GDMCC No.66556. The metabolic product of the bacillus licheniformis YL-001 provided in the application has the abilities of significantly inhibiting secretion of inflammatory factors and growth of streptococcus pneumoniae and hemolytic streptococcus b, and can improve the total antioxidant capacity of serum. The strain has good biocompatibility and high safety, has important significance for development of anti-inflammatory or antibacterial drugs, health products and food, and is especially suitable for preparation of products with throat-protecting effects.

The application provides a quality control for detecting respiratory pathogen nucleic acid, which comprises any one or more of the following respiratory pathogens: coronavirus, influenza virus, adenovirus, Mycoplasma pneumoniae, Streptococcus pneumoniae, rhinovirus or / and Legionella pneumophila. The full-length genome sequence of the coronavirus is divided into 6 target fragments, each with a length of 4000-5500 bp. The quality control of the application covers all detection target sequences (or target points) of the coronavirus, has a wide coverage, comprehensively detects target points, and does not have the phenomenon of missed detection. The quality control of the application contains main respiratory pathogen infections, has a wide range, and uses real virus samples and lentivirus samples as raw materials, and has more accurate detection target points. The preparation of the coronavirus quality control of the application integrates the target gene sequence into the host genome through the lentivirus vector, knocks out the self-replication gene in the preparation process, and has a "self-inactivation" ability, so that the recombinant lentivirus cannot replicate in the target cells and infect other cells.

The invention provides a 19F streptococcus pneumoniae invasiveness risk prediction method, and relates to the technical field of molecular biology. Wherein the evaluation marker combination comprises a translation genome, a cell synthesis genome and a ligand transport metabolism genome; the translation genome comprises rluB and rsmE; the cell synthetic genome comprises mscL and murI; and the ligand transport metabolism genome comprises czcD, site B, mtsC and pstS. The evaluation marker combination can accurately evaluate the invasive risk of serotype 19F streptococcus pneumoniae, and realizes molecular typing and risk prediction. The kit has high sensitivity and specificity, is suitable for high-throughput detection, and is helpful for clinical diagnosis and pathogenic mechanism research.

This invention discloses a strain of *Bacillus saeformis* H1, its culture method, and its applications, relating to the field of microbial technology. The strain was deposited on March 31, 2026, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 38117. This strain exhibits strong environmental adaptability, can stably grow under neutral to strongly alkaline conditions, and secretes antibacterial substances with low toxicity and no pathogenicity. After optimization, its optimal liquid fermentation conditions are: 5 g / L yeast extract, 10 g / L peptone, 37 g / L sucrose, pH=10, temperature 25℃, rotation speed 140 rpm, and culture time 24 h. The fermentation supernatant of this strain shows significant inhibitory effects on Gram-positive bacteria such as *Staphylococcus aureus*, methicillin-resistant *Staphylococcus aureus*, and *Streptococcus pneumoniae*, and can be prepared into drug sensitivity tablets. The *Bacillus saeformis* H1 provided by this invention can be used to prepare antibacterial drugs or antibacterial infection drugs, providing a new strategy for alleviating the problem of antibiotic resistance.

The present application relates to methods of treating or preventing infection-related immune conditions using compositions comprising IgM. In particular, the present application provides a method for treating immune complications resulting from infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. In some embodiments, the treatment of immune complications is carried out by immunomodulation. Also provided is a method for immunomodulating an infection in a patient in need thereof, characterized in that the method comprises administering a composition comprising IgM. The present application also provides a composition comprising IgM for use in the treatment of sepsis and a composition comprising IgM for use in the treatment of immune complications resulting from infection. In some embodiments, the above-mentioned infection or sepsis results from E. coli, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Clostridium difficile, Clostridium botulinum, or a combination thereof.

A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.

The invention discloses bacillus licheniformis YL-001 with anti-inflammatory and antibacterial effects and application of the bacillus licheniformis YL-001, and belongs to the technical field of biology, and the bacillus licheniformis YL-001 is separated from soil. The preservation number of the bacillus licheniformis strain is GDMCC (China General Microbiological Culture Collection Center) No.66556. A metabolite of the bacillus licheniformis YL-001 provided by the invention has obvious capabilities of inhibiting secretion of inflammatory factors and inhibiting growth of streptococcus pneumoniae and beta hemolytic streptococcus, and can improve the total antioxidant capacity of serum, and the strain is good in biocompatibility, high in safety and suitable for industrial production. The method has important significance for developing anti-inflammatory or bacteriostatic medicines, health care products and foods, and is particularly suitable for preparing products with the sore-throat relieving effect.

The invention discloses an application of a bupleurum chinense extract in preparation of an antibacterial product. According to the invention, it is found for the first time that various extracts (including aqueous extracts, ethanol extracts and extraction parts of different polar solvents) of bupleurum chinense have relatively good bacteriostatic activity on streptococcus pneumoniae, methicillin-resistant staphylococcus epidermidis, micrococcus luteus and enterococcus faecium. The antibacterial spectrums and effects of different extracts are different, and the research lays a solid foundation for developing novel anti-drug-resistant bacteria drugs and natural-source antibacterial products.

The invention discloses a betulinic acid derivative as well as a synthesis method and application thereof. According to the betulinic acid derivative, the carboxyl position of betulinic acid C-28 is subjected to structural modification, and four halogenated aniline derivatives are obtained. Wherein the derivatives b, d and e show strong activity on staphylococcus aureus, the derivatives d and e also show strong activity on vancomycin-resistant staphylococcus aureus (VRSA), and the derivative o strongly inhibits streptococcus pneumoniae. Compared with a parent skeleton, the four derivatives show significantly enhanced antibacterial efficacy. Experimental data prove that the derivatives d and e and further derivatives thereof may provide a promising strategy for resisting drug-resistant gram-positive pathogens, and the derivative d can be further developed into a novel therapeutic agent for biofilm-mediated drug-resistant infection.

The invention provides a preparation method of a beta-1, 4-N-acetyl glucosamine transferase III mediated sugar chain fixed-point coupling antibody drug conjugate, which comprises the following steps: S1, dissolving an antibody, adding beta-1, 4 galactosidase derived from Streptococcus peumoniae, reacting, and purifying to obtain a G0 glycotype antibody; s2, taking a G0 glycoform antibody, dissolving the G0 glycoform antibody, adding UDP-GlcNAz, Mn < 2 + > and human beta-1, 4-N-acetyl glucosamine transferase III, reacting, and purifying to obtain a glycosylated antibody; s3, dissolving toxin molecules in DMSO (dimethylsulfoxide), adding the dissolved toxin molecules into the linked sugar antibody for reaction, and performing ultrafiltration to obtain ADC molecules; or a one-pot enzyme method is also adopted for preparation. Beta-1, 4-galactosidase of a specific bacterium source is utilized, Beta-1, 4-N-acetyl glucosamine transferase III of a human source is utilized for the first time to prepare ADC, the whole process reaction condition is mild, the needed enzyme is easy to prepare and easy to obtain, and the prepared ADC is good in stability, high in uniformity and good in repeatability.

The present application belongs to the technical field of pharmaceutical chemistry, and particularly relates to an antibacterial small-molecule compound targeting bacterial phospholipid synthetase. The present application provides an antibacterial intervention strategy based on a novel mechanism of action, taking the key enzyme PlsY of bacterial specific membrane phospholipid synthesis as a target, and cracking the cross-resistance problem caused by the concentration of existing antibacterial drug targets. The lead compound T1 obtained by screening has strong inhibitory activity on PlsY, can effectively inhibit pathogenic bacteria such as Streptococcus pneumoniae and Staphylococcus aureus, and has better selective toxicity because the human body has no PlsY homologous protein. The compound has a novel structure and can be optimized, and can be rationally designed through structure-activity relationship, and also has inhibitory effect on plant pathogenic bacteria. The present application opens up a new antibacterial pathway, provides differentiated candidate molecules and reserves for coping with multi-drug resistant infections, and has medical and agricultural potential, and has significant innovation and practicality.

The invention belongs to the technical field of biological detection, and particularly relates to a fluorescence-quenching labeled double-chain universal probe and a mediated amplification method and application thereof. The nucleic acid detection system comprises a fluorescence-quenching labeled double-stranded universal probe, the double-stranded universal probe is composed of two complementary oligonucleotide chains, and the nucleotide sequences of the double-stranded universal probe are shown as SEQ ID NO: 1-4. According to the pathogen nucleic acid detection method based on the universal probe and the target specific anchoring primer, a real-time quantitative PCR or isothermal amplification technology and a fluorescence resonance energy transfer mechanism are integrated, and synchronous and accurate detection of mycoplasma pneumoniae, streptococcus pneumoniae, haemophilus influenzae, influenza A virus, influenza B virus, novel coronavirus and the like is achieved. The method does not need pathogen culture, solves the problems of insufficient specificity, high cost, tedious operation and the like of a traditional detection technology, and can be applied to rapid diagnosis of clinical pathogen infection, reasonable use guidance of antibiotics and epidemiological monitoring.

This invention relates to the field of compound essential oils of traditional Chinese medicine, and particularly to a compound essential oil of traditional Chinese medicine for the adjuvant intervention against Streptococcus pneumoniae and its preparation method. The raw materials include the following by weight: 3-8 parts of patchouli essential oil; 2-6 parts of clove essential oil; 2-5 parts of costus root essential oil; 2-6 parts of nard essential oil; 3-7 parts of calamus essential oil; 1-4 parts of asarum essential oil; 3-8 parts of peppermint essential oil; 2-6 parts of artemisia essential oil; 3-7 parts of eupatorium essential oil; 45-80 parts of base oil; 2-5 parts of solubilizer; and 1-3 parts of penetration enhancer. This invention addresses the core issues of "respiratory inflammation, sputum accumulation, and decreased body defense" caused by Streptococcus pneumoniae. Through the scientific formulation of active molecules from nine kinds of Chinese herbal essential oils, a comprehensive synergistic system is formed, which has the functions of "antibacterial and antiviral, anti-inflammatory and lung-clearing, expectorant and cough-relieving, and enhanced defense." It features strong synergistic activity of active molecules, high specificity, high retention and utilization rate of active molecules, safe and convenient use, wide applicability, and simple preparation process.

The invention provides an engineering bacterium for producing vitamin B6 as well as a construction method and application of the engineering bacterium. Specifically, the engineering bacterium contains an exogenous 5 '-phosphopyridoxal synthetase expression cassette, the expression cassette contains a PdxST gene module or a PdxTS gene module, and the PdxST gene module and the PdxTS gene module respectively and independently contain the following genes: a PdxS gene and a PdxT gene; wherein the PdxS gene and the PdxT gene are respectively and independently derived from microorganisms selected from the following group: streptococcus pneumoniae, staphylococcus aureus, bifidobacterium animalis, haematococcus acidilactici, nocoryococcus martensii or a combination thereof. The engineering bacterium greatly improves the production efficiency of the vitamin B6, is suitable for large-scale industrial production, and has great application and popularization values.

The present invention relates to a vaccine composition for prophylactic use against infections caused by Streptococcus pneumoniae. It contains inactivated bacteria of Escherichia coli, Morganella morganii, Proteus mirabilis, Klebsiella pneumoniae, and Enterococcus faecalis, and preferably dextran and an aluminum compound as adjuvant.

The present invention relates to the field of immunotherapeutics. It provides a method for characterisation and quality control, in particular for determining the potency of an immunoglobulin composition comprising immunoglobulins derived from a plurality of human donors, the method comprising contacting the immunoglobulin composition with pneumolysin, adding erythrocytes to the immunoglobulin composition and determining lysis of the erythrocytes. The invention also provides a corresponding use of pneumolysin, as well as a kit and composition useful in said method. The method can be used for quality control of immunoglobulin concentrate, e.g., of an IgM-containing immunoglobulin composition comprising IgM, IgA and IgG antibodies, and in a method of preparing an immunoglobulin composition. The immunoglobulin compositions obtainable from said method may be used, e.g., in the treatment of pneumonia, e.g., severe community-acquired pneumonia, which may be caused, e.g., by Streptococcus pneumoniae.

The application provides a primer composition, a kit and application thereof for efficiently detecting common pathogenic bacteria of human, relates to the technical field of microorganism gene detection, and aims at solving the defects of low detection efficiency, poor specificity, low sensitivity of traditional PCR technology, and non-specific amplification of traditional LAMP detection technology. The application designs primers according to known sequences of six common pathogenic bacteria of human, i.e., Candida albicans, Chlamydia trachomatis, Escherichia coli, group B streptococcus, Mycoplasma hominis and Streptococcus pneumoniae, and provides a kit with a micro-fluidic chip as a carrier and application thereof, which are used for detecting common pathogenic bacteria of human, have high specificity and high sensitivity, reduce detection cost and detection time, and can realize on-site rapid detection of common pathogenic bacteria of human.

Provided herein is a protein, referred to as a Pn3Pase protein, that degrades the capsular polysaccharide of serotype 3 Streptococcus pneumoniae. The disclosure includes a genetically modified cell that includes a Pn3Pase protein, and compositions that include the protein, the polynucleotide encoding the protein, the genetically modified cell, or a combination thereof. Also provided are methods for using a Pn3Pase protein, including methods for contacting a S. pneumoniae having a type III capsular polysaccharide with a Pn3Pase protein, increasing deposition of at least one complement component on the surface of a S. pneumoniae, treating an infection in a subject, treating a symptom in a subject, decreasing colonization of a subject by S. pneumoniae, or a combination thereof.

The present application belongs to the field of microbial technology, and particularly relates to an antiviral and antibacterial composition, a preparation method and application thereof. The composition comprises at least the following components: Rhizopus oryzae CICC 41440 and Rhizopus japonicus CICC 41297, fermentation products thereof and / or organic solvent extracts thereof. The drug composition can synergistically inhibit rotavirus, Streptococcus pneumoniae, adenovirus and Klebsiella pneumoniae and other pathogens, and has low cytotoxicity and high biological safety. The drug composition can effectively improve the prevention and treatment level of intestinal diseases and respiratory diseases mediated by the above pathogens, and therefore has good practical application value.

The present application relates to the technical field of microfluidics, and particularly relates to a kit for rapidly detecting 15 respiratory pathogens and a use method thereof.The kit comprises a plurality of reaction cavities, each of which has a primer group corresponding to 15 respiratory pathogens; the primer group comprises inner primers, outer primers and loop primers for PCR amplification of Mycoplasma pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Stenotrophomonas maltophilia, Haemophilus influenzae, Streptococcus pneumoniae, Escherichia coli, Legionella pneumophila, Burkholderia, Staphylococcus aureus, Corynebacterium striatum, Aspergillus, Pneumocystis jirovecii and Candida albicans.The present application can simultaneously detect 15 respiratory pathogens by adding samples once, avoids adding liquid reagents to multiple detection tubes, reduces the intensity of manual operation and the risk of mismatch.

The present application aims to provide a eucheuma extract, a preparation method and application thereof, and the preparation method comprises the following steps: cutting eucheuma whole grass, using distilled water and 75% ethanol as extraction solvents respectively, hot reflux extraction twice, combining the filtrates, concentrating under reduced pressure, and evaporating the solvent to dryness to prepare a dry paste, and obtaining eucheuma water extract and eucheuma alcohol extract respectively. The eucheuma water extract and alcohol extract provided by the present application have significant inhibitory effects on staphylococcus aureus, escherichia coli, staphylococcus epidermidis, methicillin-resistant staphylococcus epidermidis, sarcina, bacillus, pseudomonas aeruginosa, enterococcus faecium, micrococcus luteus, acinetobacter baumannii, streptococcus pneumoniae and klebsiella pneumoniae, and have great development potential in the future research on bacteriostatic drugs, bacteriostatic cleaning products and other bacteriostatic products.

Provided herein are methods, immunogenic combinations, immunogenic compositions and uses thereof relating to co-administration of an immunogenic composition comprising a recombinant RSV antigen comprising a soluble F protein comprising at least one modification that stabilizes a pre-fusion conformation of the F protein; and an immunogenic composition comprising at least one glycoconjugate from each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F.

The invention relates to a clarithromycin derivative containing a quinolone structure as well as a preparation method and application of the clarithromycin derivative. The compound provided by the invention has antibacterial activity equivalent to that of telithromycin in constitutive streptococcus pneumoniae drug-resistant bacteria and streptococcus pyogenes drug-resistant bacteria. And the antibacterial activity on haemophilus influenzae is better than that of Thailimycin. Furthermore, the anti-streptococcus pyogenes 12-206 activity of part of the compounds disclosed by the invention is obviously superior to that of the existing compounds. In addition, the compound provided by the invention not only can act on ribosome, but also can act on topoisomerase, and is a double-target compound at the cellular level. Therefore, the compound disclosed by the invention is not easy to induce bacteria to generate mutation, and the service life of the compound as an antibacterial agent can be prolonged.

The application discloses a lactobacillus plantarum resisting multiple drug-resistant bacteria and application thereof, and a lactobacillus plantarum 6-14 is separated from collected wild bird excrement, the bacterium has obvious inhibiting effect on multiple drug-resistant bacteria and non-drug-resistant bacteria, including inhibiting methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus faecalis, penicillin-resistant streptococcus pneumoniae, staphylococcus aureus, escherichia coli, salmonella enteritidis and salmonella typhimurium, and the application lays a foundation for developing good antibacterial probiotic preparations.